yersinia
pesti
etiolog
agent
plagu
kill
million
peopl
throughout
record
histori
mankind
antibiot
may
provid
littl
immedi
relief
patient
high
bacteremia
patient
infect
antibiot
resist
strain
plagu
two
virul
factor
pesti
capsid
protein
lowcalcium
respons
lcr
vprotein
vantigen
proven
target
activ
passiv
immun
mous
monoclon
antibodi
mab
vantigen
passiv
protect
mice
murin
model
plagu
howev
antiyersinia
pesti
monoclon
antibodi
avail
prophylact
therapeut
treatment
human
identifi
one
human
mab
two
antivspecif
human
mab
pan
phagedisplay
fab
librari
vantigen
fab
convert
bind
protect
activ
evalu
bound
weakli
peptid
locat
nterminu
protect
mous
mab
also
bind
bound
strongli
vantigen
peptid
indic
linear
epitop
bind
peptid
panel
peptid
suggest
epitop
may
conform
show
better
protect
pesti
challeng
plagu
mous
model
synergist
effect
observ
three
antibodi
combin
incomplet
complet
protect
achiev
given
differ
time
postchalleng
antibodi
studi
determin
potenti
therapeut
prophylact
pesti
infect
human
openaccess
articl
distribut
term
creativ
common
public
domain
declar
stipul
place
public
domain
work
may
freeli
reproduc
distribut
transmit
modifi
built
upon
otherwis
use
anyon
law
purpos
yersinia
pesti
pesti
caus
agent
plagu
kill
estim
million
peopl
previou
pandem
current
incid
plagu
low
anim
reservoir
pesti
exist
worldwid
sporad
case
report
recent
averag
case
number
worldwid
pesti
render
airborn
potenti
use
bioweapon
recogn
categori
agent
niaid
list
biodefenserel
pathogen
current
treatment
plagu
consist
antibiot
live
attenu
vaccin
plagu
use
former
soviet
union
prevent
nevertheless
live
attenu
wholecel
vaccin
kill
wholecel
vaccin
advers
effect
vari
degre
though
type
treatment
efficaci
need
altern
treatment
plagu
multipleantibioticresist
isol
pesti
isol
drug
resist
shown
mediat
selftransfer
plasmid
subunit
vaccin
consist
two
virul
factor
protein
vantigen
current
human
clinic
trial
studi
involv
vaccin
antigen
variou
format
provid
proofofconcept
data
humor
respons
effici
protect
pesti
multipl
report
mous
antiplagu
monoclon
antibodi
mab
pesti
challeng
passiv
protect
mous
plagu
therefor
mab
therapi
may
attract
altern
exist
treatment
plagu
despit
promis
possibl
remain
major
hurdl
treatment
plagu
possibl
immun
respons
human
mous
mab
current
avail
one
possibl
amelior
immun
respons
mous
mab
human
mab
use
human
anoth
altern
develop
new
fulli
human
antiplagu
monoclon
antibodi
clinic
usag
describ
isol
three
mab
larg
naiv
human
phagedisplay
fab
librari
one
design
two
vantigen
use
alon
display
good
protect
effect
wherea
howev
clear
synergist
effect
found
use
togeth
maximum
protect
alon
could
achiev
alter
antibodi
administr
schedul
first
report
describ
isol
fulli
human
antiplagu
mab
show
efficaci
mous
model
plagu
antibodi
repres
signific
breakthrough
toward
possibl
adjunct
therapeut
treatment
pesti
infect
human
antigen
plate
format
yield
posit
fab
clone
four
round
select
antigen
sequenc
clone
confirm
ident
design
vantigen
plate
bead
format
yield
two
posit
fab
clone
four
round
select
format
one
clone
format
design
respect
select
analysi
sequenc
analysi
reveal
heavi
light
chain
origin
germlin
respect
origin
mutat
rate
rang
zero
less
typic
antibodi
isol
human
librari
pan
virus
caus
acut
infect
contrast
neutral
antibodi
select
immun
human
librari
pan
caus
chronic
infect
clone
transform
cell
respect
fab
express
purifi
figur
convers
express
clone
three
antibodi
clone
transient
transfect
freestyl
hek
cell
express
purifi
figur
determin
specif
affin
select
antibodi
elisa
fab
igg
format
conduct
describ
method
fab
igg
bound
respect
antigen
specif
without
crossreact
antigen
test
figur
fab
igg
appar
affin
low
subnm
rang
respect
fab
appar
affin
approxim
nm
figur
igg
howev
subnm
appar
affin
avid
avid
effect
pronounc
three
antibodi
low
level
competit
human
antiv
fab
mous
antiv
mab
three
human
antiplagu
fab
use
competitionelisa
panel
mous
antiplagu
mab
mous
antiplagu
mab
includ
mab
five
antiv
mab
includ
antiv
mab
highli
protect
found
appar
competit
human
antiv
fab
mous
antiv
mab
figur
howev
observ
weak
competit
human
antiv
fab
antibodi
mous
antiv
mab
see
human
antiv
fab
antibodi
figur
competit
human
fab
antibodi
mous
mab
also
minim
figur
ran
two
control
competit
studi
human
mous
mab
one
control
add
primari
antibodi
label
nc
figur
second
control
use
nonspecif
mous
isotyp
mab
competit
assay
label
bm
burkholderia
mallei
mab
also
lack
competit
human
antiv
fab
antibodi
suggest
two
human
antiv
fab
recogn
differ
epitop
one
may
conform
vantigen
figur
note
howev
competitionelisa
perform
differ
fashion
name
human
antiv
mab
allow
bind
respect
antigen
ad
mous
antiv
mab
moder
competit
detect
human
mous
mab
well
human
antiv
mous
antiv
mab
data
shown
character
bind
human
antiv
mab
vantigen
respect
close
examin
bind
human
mab
two
separ
panel
overlap
peptid
one
panel
cover
fulllength
antigen
peptid
v
antigen
peptid
human
mab
weakmoder
bind
signal
peptid
locat
nterminu
figur
suggest
mab
may
also
recogn
conform
region
involv
peptid
bind
human
antiv
mab
result
strong
signal
peptid
weak
signal
peptid
figur
antiv
mab
bind
peptid
suggest
epitop
may
conform
figur
initi
studi
saw
weak
bind
peptid
repeat
bind
studi
human
antiv
mab
see
bind
peptid
might
explain
weak
competit
mous
antibodi
recogn
divers
epitop
vantigen
figur
posit
signal
seen
mab
vantigen
peptid
number
nonspecif
signal
gener
secondari
antibodi
amemiya
et
al
unpublish
epitop
mous
antibodi
also
determin
peptid
bind
assay
amemiya
et
al
unpublish
data
consist
competitionelisa
present
studi
test
human
antiv
igg
bind
respect
target
bacteri
cell
perform
flow
cytometri
analysi
mous
mab
human
mab
bound
specif
pesti
grown
strain
grown
neither
bind
control
e
coli
strain
grown
figur
bottom
panel
consist
previou
report
express
regul
temperatur
express
rt
human
antiv
mab
show
minor
bind
pesti
grown
although
normal
see
bind
human
antiv
mous
antiv
mab
includ
amemiya
unpublish
mous
isotyp
control
mab
show
bind
wholecel
includ
show
bind
mous
human
mab
antibodi
specif
confirm
bind
data
use
immunofluoresc
techniqu
result
consist
flow
cytometri
data
mous
human
mab
bound
pesti
wholecel
figur
neither
human
antiv
mab
figur
mous
antiv
mab
like
data
shown
control
sampl
figur
nonspecif
mous
isotyp
figur
primari
mab
show
signific
bind
pesti
human
v
mab
protect
synergist
pesti
challeng
bubon
plagu
model
abil
human
antiv
mab
passiv
protect
mice
pesti
infect
evalu
bubon
plagu
model
human
antiv
mab
use
either
separ
togeth
differ
combin
mab
given
mice
separ
challeng
pesti
human
mab
show
efficaci
meantimetodeath
mtd
mabtreat
mice
shift
day
survivor
compar
mice
given
normal
mous
serum
nm
mtd
day
survivor
figur
unlik
howev
human
antiv
mab
show
signific
protect
meantimetodeath
mtd
day
survivor
day
survivor
respect
compar
nm
treat
mice
mous
antiv
control
mab
passiv
protect
mice
challeng
condit
mtd
day
human
antiv
mab
given
mice
passiv
figur
improv
protect
challeng
observ
mtd
day
survivor
similar
seen
nmstreat
mice
mtd
day
survivor
howev
human
mab
mtd
day
survivor
given
togeth
two
human
antiv
mab
greater
number
mice
passiv
protect
mtd
survivor
antibodi
use
separ
suggest
synergist
effect
although
saw
protect
human
mab
synergist
protect
effect
human
mab
given
human
mab
bubon
plagu
model
wonder
effect
posit
neg
nonspecif
human
mab
combin
human
mab
number
survivor
mous
model
plagu
answer
question
inject
five
group
mice
follow
mab
one
group
mice
nonspecif
human
mab
mg
anoth
group
mice
mous
mab
mg
anoth
group
mice
human
mab
mg
two
group
mice
includ
given
either
mg
mg
nonspecif
mab
mg
one
day
challeng
pesti
figur
mice
group
receiv
nonspecif
mab
die
day
similar
control
antibodi
mous
group
figur
number
survivor
obtain
whether
mice
given
mous
mab
combin
nonspecif
seen
previous
figur
mice
surviv
group
receiv
human
mab
human
mab
combin
nonspecif
mab
obtain
one
survivior
obtain
without
nonspecif
mab
variat
number
survivor
differ
saw
previous
figur
addit
mtd
affect
presenc
nonspecif
day
given
mab
day
result
suggest
nonspecif
mab
littl
effect
surviv
mice
given
human
mab
mous
mab
delay
time
deliveri
human
antiplagu
mab
provid
better
protect
plagu
challeng
one
possibl
reason
observ
less
protect
human
antiv
mab
mous
plagu
model
level
human
igg
may
sustain
mous
time
compar
mous
igg
mab
test
hypothesi
two
separ
studi
first
examin
concentr
human
antibodi
mice
directli
measur
level
antiv
serum
given
human
mab
ip
inject
mous
sera
collect
differ
time
point
initi
dose
human
igg
level
monitor
direct
elisa
seen
figur
mab
appear
halflif
approxim
day
halflif
mab
approxim
day
day
level
two
human
antibodi
undetect
contrast
level
mous
antiv
mab
may
decreas
initi
like
human
antiplagu
mab
day
level
still
approxim
initi
concentr
figur
halfliv
human
igg
mab
mice
report
similar
found
anoth
studi
human
mab
use
anoth
biothreat
agent
contrast
human
igg
molecul
would
averag
serum
half
life
day
human
find
administ
mab
differ
time
point
rel
time
challeng
origin
regimen
provid
consist
modest
protect
administr
human
mab
hour
postchalleng
provid
increas
protect
hour
schedul
provid
complet
protect
figur
antibodi
administr
even
later
time
point
perform
sinc
mice
began
die
day
challeng
without
treatment
howev
evalu
effect
second
dose
antibodi
later
time
point
group
mice
first
receiv
initi
dose
human
mab
hour
challeng
done
earlier
protocol
mice
receiv
second
dose
human
mab
day
challeng
increas
number
survivor
mtd
epitop
map
human
antiv
antibodi
peptid
bind
assay
twentyseven
peptid
cover
full
length
use
coat
elisa
plate
ml
mgml
solut
peptid
bind
human
mab
ml
mgml
solut
analyz
sampl
label
fulllength
antigen
use
coat
plate
posit
control
ml
mgml
solut
sampl
label
media
neg
control
primari
antibodi
ad
b
c
fiftytwo
peptid
cover
full
length
vantigen
use
coat
elisa
plate
ml
mgml
solut
human
antiv
b
c
mab
use
ml
mgml
solut
respect
analyz
bind
sampl
label
v
posit
control
ml
mgml
solut
sampl
label
media
neg
control
without
primari
antibodi
day
approach
efficaci
display
singl
dose
administ
hour
challeng
data
suggest
optimum
serum
concentr
human
critic
depend
time
administr
optimum
concentr
human
antiplagu
turn
determin
outcom
treatment
protocol
antibiot
forefront
combat
bacteri
infect
decad
great
success
howev
develop
new
antibiot
struggl
keep
pace
emerg
drug
resist
bacteri
strain
exampl
pesti
intens
interest
develop
antibodybas
therapi
altern
method
treatment
initi
antibodybas
therapi
mostli
limit
treat
cancer
immun
disord
howev
better
understand
pathogenesi
infecti
agent
advanc
develop
protect
neutral
antibodi
use
antibodybas
therapi
infecti
agent
becom
frequent
report
describ
first
isol
fulli
human
mab
pesti
figur
human
antiv
mab
show
synergist
protect
use
togeth
murin
bubon
plagu
model
human
mous
antiv
mab
given
ip
mice
hr
parenter
challeng
pesti
number
surviv
mice
treatment
group
monitor
day
challeng
follow
antibodi
amount
use
normal
mous
serum
nm
mg
mous
mg
mous
antiv
mg
human
mg
human
antiv
mg
follow
mab
amount
use
nm
mg
mg
mg
mg
mg
virul
factor
vantigen
previou
studi
shown
mous
mab
effect
protect
mice
pesti
howev
mous
mab
safe
use
present
form
human
particular
concern
immun
reaction
mous
primari
antibodi
sequenc
human
system
may
lead
sever
advers
effect
time
reduc
potenti
benefit
highli
desir
fulli
human
antibodi
reason
fulli
human
report
display
moder
good
protect
bubon
plagu
challeng
pesti
hand
two
antiv
mab
use
separ
show
efficaci
use
togeth
combin
human
antiplagu
mab
result
better
protect
overal
suggest
synergist
effect
antibodi
similar
effect
report
studi
use
mous
antiv
mab
mous
model
plagu
case
human
mab
gave
mice
human
mab
day
challeng
saw
greater
protect
plagu
challeng
could
achiev
suggest
mainten
serum
concentr
human
mab
mous
possibl
one
critic
factor
better
protect
kinet
studi
reveal
inde
serum
concentr
human
antibodi
drop
mous
antiplagu
mab
cours
studi
also
plausibl
human
antiplagu
mab
might
bind
mous
antigen
nonspecif
thu
decreas
amount
free
circul
human
antiplagu
antibodi
mous
figur
nonspecif
human
antibodi
littl
effect
meantimetodeath
mtd
number
surviv
mice
receiv
human
mab
nonspecif
human
human
mous
antiv
mab
given
ip
mice
hr
parenter
challeng
pesti
number
surviv
mice
treatment
group
monitor
day
challeng
mous
human
mab
amount
given
follow
group
mice
nonspecif
human
mg
mg
mg
mg
mg
mg
mg
anoth
import
underli
factor
effici
protect
antibodi
epitop
antibodi
recogn
although
human
mab
appear
bind
region
mous
aminotermin
end
amemiya
et
al
unpublish
could
demonstr
direct
competit
two
antibodi
speci
observ
may
result
natur
antibodi
bind
site
epitop
sever
mous
mab
isol
independ
recogn
region
epitop
behav
manner
amemiya
et
al
unpublish
may
mab
bound
aminotermin
end
may
readili
come
protein
may
dissoci
slowli
whether
bind
site
involv
linear
conform
site
known
mous
human
mab
bound
whole
antigen
well
weakli
moder
nevertheless
human
mab
protect
mous
mab
human
mab
given
challeng
also
report
neutral
epitop
vantigen
locat
region
span
amino
acid
possibl
minor
secondari
neutral
epitop
exist
near
aminotermin
region
vantigen
neither
human
antiv
antibodi
report
compet
mous
antiv
antibodi
effici
minor
competit
human
antiv
fab
antibodi
mous
antiv
antibodi
suggest
recognit
site
human
antiv
antibodi
slightli
differ
may
partial
share
conform
bind
site
differ
might
one
reason
inabl
protect
effici
human
mab
exactli
human
mab
abl
protect
mice
may
directli
relat
presenc
antigen
surfac
plagu
organ
report
antiphagocyt
abil
macrophag
take
plagu
organ
directli
relat
lack
resist
phagocytosi
relat
presenc
bind
human
mab
surfac
plagu
bacilli
opson
may
trigger
phagocytosi
encapsul
bacilli
macrophag
therebi
allow
phagocyt
cell
clear
host
pathogen
exact
mechan
vantigen
exert
virul
complet
known
report
show
vantigen
secret
growth
medium
secret
import
virul
secret
vantigen
medium
describ
depend
contact
host
cell
could
also
direct
host
cell
yersinia
outer
protein
yop
depend
secret
ysc
type
iii
system
ttss
also
suggest
free
vantigen
may
enter
cell
endocytosi
besid
inject
cell
ysc
ttss
insid
hostcel
know
exactli
host
protein
interact
intracellular
vantigen
nevertheless
evid
antiv
antibodi
enhanc
phagocytosi
possibl
fc
receptor
therebi
block
yop
deliveri
host
cell
thu
prevent
ysc
depend
ttss
inject
vantigen
host
cell
studi
howev
abl
detect
bind
human
antiv
mab
surfac
pesti
cell
flow
cytometri
fluoresc
microscopi
suggest
vantigen
bacteri
cell
surfac
condit
use
studi
express
level
vantigen
level
detect
discuss
previous
howev
presenc
vantigen
surfac
cell
may
depend
contact
eukaryot
host
cell
highli
specif
region
neutral
epitop
vantigen
suggest
possibl
ligandreceptor
interact
vantigen
cellular
factor
indic
perhap
vantigen
exert
biolog
effect
mechan
mediat
ttss
pathway
conclus
human
antiplagu
antibodi
report
repres
perhap
one
closest
practic
clinic
use
may
safer
effici
human
system
due
fulli
human
natur
like
longer
halflif
human
also
intraven
applic
antibodi
human
may
rapid
deliveri
system
may
augment
antibiot
treatment
plagueexpos
individu
final
affin
three
antibodi
increas
use
readili
avail
techniqu
may
reduc
dose
requir
effici
protect
success
develop
three
human
antiplagu
figur
postchalleng
administr
human
mab
confer
better
protect
human
mab
administ
pesti
challeng
mice
monitor
day
challeng
mous
antiv
mab
mg
use
posit
control
mab
normal
human
serum
nh
mg
use
neg
control
mice
per
group
number
behind
antibodi
repres
time
day
antibodi
administ
mg
mice
rel
day
challeng
day
two
number
human
repres
two
differ
day
mab
mg
ad
group
mice
rel
day
challeng
antibodi
model
suggest
new
potent
antiv
antibodi
potenti
develop
use
approach
restrict
vantigen
subunit
fragment
contain
critic
neutral
epitop
perhap
virul
factor
pesti
strain
use
challeng
studi
origin
obtain
quan
center
diseas
control
prevent
fort
collin
co
isol
sputum
human
case
pneumon
plagu
pesti
grown
inoculum
prepar
challeng
essenti
describ
previous
pesti
pgmstrain
origin
isol
pesti
use
antibodi
bind
studi
describ
obtain
susan
l
welko
usamriid
frederick
md
pesti
purifi
v
protein
antigen
obtain
brad
powel
usamriid
fort
detrick
frederick
md
array
cover
amino
acid
overlap
obtain
biodefens
emerg
infect
research
resourc
repositori
bei
manassa
va
array
cover
vantigen
amino
acid
overlap
obtain
bei
mous
mab
provid
georg
anderson
usamriid
antiv
mous
mab
well
control
mous
antiburkholderia
mallei
bm
antibodi
obtain
sylvia
trevino
usamriid
antiv
mous
mab
obtain
jim
hill
porton
wiltshir
uk
use
competit
elisa
posit
control
mous
passiv
protect
experi
mice
mab
isotyp
human
control
mab
use
passiv
protect
studi
antihuman
igfii
mab
purifi
vprotein
either
coat
directli
maxisorp
plate
nunc
denmark
pb
buffer
overnight
plate
format
pan
biotinlabel
first
ezlink
sulfonhslcbiotin
pierc
rockford
il
streptavidinconjug
magnet
bead
format
pan
label
perform
accord
manufactur
recommend
protocol
plate
format
approxim
fab
display
surfac
phage
amplifi
larg
naiv
librari
suspend
pb
dri
milk
appli
well
coat
vprotein
incub
hour
room
temperatur
well
wash
time
first
round
time
subsequ
four
round
phage
rescu
cell
exponenti
growth
phase
bead
format
biotinlabel
vantigen
first
incub
amount
phage
plate
format
ml
dri
milk
suspens
room
temperatur
hour
fifteen
ml
dynabead
myon
streptavidin
invitrogen
dynal
oslo
norway
preblock
dri
milk
ad
antigenphag
mixtur
one
hour
room
temperatur
bead
wash
time
pb
first
round
time
subsequ
four
round
select
phage
rescu
cell
total
four
round
perform
antigen
format
monoclon
elisa
perform
select
posit
clone
one
hundr
clone
screen
antigen
format
clone
display
select
plasmid
prepar
sequenc
express
purif
convers
gener
stabl
clone
clone
select
describ
transform
ecoli
strain
express
briefli
singl
clone
inocul
supplement
unit
ampicillin
glucos
incub
shake
reach
iptg
ad
achiev
final
concentr
mm
cultur
shift
shake
incub
overnight
cell
collect
lyse
polymyxin
b
sigma
st
loui
pb
mixtur
subject
ninta
agaros
bead
qiagen
hilden
germani
purif
product
heavi
light
chain
respect
fab
clone
bicistron
express
vector
kindli
provid
denni
burton
scripp
research
institut
la
jolla
ca
small
scale
product
transient
transfect
express
freestyl
hek
cell
invitrogen
carlsbad
ca
use
larg
scale
product
stabl
clone
gener
use
atcc
manassa
va
cell
briefli
heavi
light
chain
three
human
antiplagu
clone
vector
transfect
cell
one
day
transfect
cell
replat
subject
select
gmem
medium
supplement
mm
msx
two
week
later
msx
resist
clone
amplifi
clone
test
express
respect
adapt
growth
serumfre
medium
hyclon
logan
ut
supplement
mm
msx
serumfre
growth
medium
collect
pass
protein
asepharos
resin
column
purif
elisa
assay
use
assess
bind
abil
fab
briefli
vantigen
coat
costar
high
bind
plate
corn
corn
ny
incub
overnight
next
day
plate
block
dri
milk
pb
serial
dilut
fab
igg
appli
plate
incub
plate
one
hour
antihishors
radish
peroxidas
hrp
fab
detect
antihumanfchrp
igg
detect
dri
milk
ad
plate
incub
anoth
hour
plate
wash
four
time
abt
substrat
roch
mannheim
germani
ad
approxim
min
room
temperatur
taken
competit
studi
mous
mab
human
fab
antigen
mgml
vantigen
use
coat
plate
immulon
thermo
electron
milford
plate
incub
overnight
wash
plate
block
solut
bovin
serum
albumin
tween
pb
ad
plate
plate
incub
hr
flaglabel
human
fab
biotinylatedmous
mab
allow
bind
antigen
simultan
hr
detect
presenc
human
fab
conjug
use
detect
amount
biotinyl
mous
mab
present
streptavidinconjug
hrp
ad
hr
ad
hydrogen
solut
color
reaction
allow
develop
room
temperatur
min
read
nm
analysi
bind
vantigen
peptid
peptid
ad
plate
ml
per
well
mgml
plate
incub
overnight
immunlon
plate
wash
block
step
describ
bind
human
mous
mab
igg
detect
describ
bind
mab
peptid
evalu
mgml
flow
cytometri
use
analyz
bind
human
antiv
antigen
pesti
pgmwholecel
pesti
pgmwa
first
streak
onto
sheepblood
agar
plate
grown
room
temperatur
rt
day
coloni
readili
visibl
singl
coloni
pick
inocul
ml
heart
infus
broth
remel
lenexa
ks
contain
xylos
mm
cacl
cell
grown
overnight
rt
rigor
shake
next
day
aliquot
bacteria
cultur
shift
remain
rt
cultur
allow
continu
anoth
hour
bacteria
collect
suspend
pb
ten
ml
bacteri
cell
mix
ml
fc
block
solut
pb
fc
mgml
fcblock
bd
bioscienc
achiev
final
densiti
cellsml
human
mous
igg
ad
bacteri
cell
suspens
final
concentr
mgml
incub
min
bacteri
cell
collect
centrifug
suspend
ml
pb
cell
wash
twice
bacteri
cell
suspend
fc
block
solut
secondari
antibodi
includ
either
goat
antimous
iggfitc
pierc
rockford
il
goat
antihuman
iggfitc
southern
biotech
birmingham
al
ad
cell
dilut
min
cell
wash
three
time
pb
subject
immedi
fac
analysi
use
facscalibur
bd
bioscienc
san
diego
ca
cell
fix
paraformaldehyd
detect
antibodi
bind
wholecel
immunofluoresc
microscopi
growth
pesti
pgmand
sampl
prepar
bind
human
mous
antiv
mab
ident
fac
analysi
except
nikon
fluoresc
microscop
nikon
instrument
inc
melvil
ny
use
detect
passiv
protect
human
mous
antiv
mab
pesti
challeng
studi
antibodi
evalu
efficaci
plagu
challeng
given
intraperiton
ip
mg
per
mous
except
state
differ
figur
legend
week
old
balbc
mice
h
challeng
time
point
postchalleng
indic
figur
legend
challeng
dose
prepar
frozen
stock
pesti
streak
tryptos
blood
agar
slant
incub
h
incub
period
slant
rins
mm
potassium
phosphat
buffer
ph
cell
densiti
adjust
requir
densiti
buffer
mice
given
challeng
dose
ld
subcutan
ml
ld
equal
cfu
observ
least
day
research
conduct
complianc
anim
welfar
act
feder
statu
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
facil
research
conduct
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
studi
involv
mice
approv
iacuc
us
armi
medic
research
institut
infecti
diseas
anim
protocol
number
halflif
human
mous
antiv
mab
given
passiv
mice
elisa
describ
use
detect
amount
human
mous
antiv
mab
present
mice
time
briefli
protein
mgml
carbon
buffer
ph
use
coat
plate
immulon
overnight
wash
block
twofold
dilut
mous
serum
taken
retroorbit
ip
administr
mab
made
pb
bsa
ad
plate
incub
hr
wash
amount
human
mous
antiv
mab
bind
antigen
detect
addit
goatantihuman
goatantimous
igg
conjug
hrp
southern
biotechnolog
result
mice
time
point
mab
perform
triplic
report
mean
reciproc
highest
dilut
give
mean
od
least
least
twice
standard
deviat
sd
